Latest News Archive

Please select Category, Year, and then Month to display items
Categories
UFS News Media Release Research
Years
2017 2018 2019 2020 2021 2022 2023 2024
Months
January February March April May June July August September October November December
Previous Archive
31 May 2018 Photo Anja Aucamp
Microbiology department receives Research Chair in Pathogenic Yeasts Prof Carlien Pohl-Albertyn
Prof Carlien Pohl-Albertyn, Professor in the Department of Microbial, Biochemical and Food Biotechnology

The National Research Foundation (NRF) recently approved a fifth research chair for the University of the Free State (UFS), the Research Chair in Pathogenic Yeasts. Prof Carlien Pohl-Albertyn from the Department of Microbial, Biochemical and Food Biotechnology, will be chairing this research chair. 

Activities of the Research Chair in Pathogenic Yeasts builds on existing research strengths and will contribute towards understanding pathobiology of medically significant pathogenic yeasts belonging to the genera Candida and Cryptococcus. 

According to Prof Pohl-Albertyn, the research group, established in 2014, is the only one in South African focusing on understanding the role of bioactive lipids in host-pathogen interaction as well as in the search for novel drug targets. The group brought together three principal investigators, Prof Pohl-Albertyn, Prof Koos Albertyn and Dr Olihile Sebolai, with knowledge regarding various virulence factors (including immunomodulatory metabolites) produced by the Candida and Cryptococcus as well as molecular biology of yeasts. Besides the three principal investigators, the group also includes five PhD students, nine MSc students, four BSc honours students as well as two postdoctoral fellows. 

Current projects of the group include the production of immunomodulatory compounds by the yeasts, finding novel targets for antifungal drugs and the interaction between the yeasts and different hosts using a variety of infection models. In addition, the interaction between pathogenic yeasts and other co-infecting pathogens is also being investigated. 

Why research on fungal infections?
“As a result of presently used treatments for diseases and HIV/Aids, and the advances in medical interventions, many diseases no longer pose a threat to humans and life expectancy is prolonged. However, this has also caused an increase in various opportunistic infections, and most of all, fungal infections.

“With an increase in the number of individuals sensitive to invasive fungal infections, yeasts have begun to be reported more frequently as pathogens (yeasts that can cause disease). Infections by pathogenic yeasts affect a wide variety of patients. Although most of them are immunosuppressed (including HIV positive) other underlying conditions may predispose people to such infections. These include extremes of age (premature infants and the elderly), diabetes, cancer and cystic fibroses. In addition, patients hospitalised in intensive care units, as well as patients undergoing major abdominal or thoracic surgery are at high risk of invasive candidiasis. Similarly, HIV/Aids, liver cirrhosis and immunosuppressive therapy are known risk factors for invasive cryptococcosis,” said Prof Pohl-Albertyn.

According to her an important hurdle in the treatment of invasive yeast infection is the emergence of drug resistance in these pathogens. Therefore, research into pathobiology, including new drug targets, as well as novel treatment options, is a necessity. 

In line with the UFS research strategy
The NRF call for research chairs, specifically aimed at female researchers at universities that currently have fewer than 15 research chairs, came out in May 2017.

The university considers the current SARChi Chairs and the possibility of future chairs as an integral and strategic initiative to increase its national and international standing through excellent academic and research leadership. A Research Chair in Pathogenic Yeasts is therefore an invaluable addition to the UFS Research Strategy. 

The Research Chair is for five years, and is renewable for three terms.

Microbiology from University of the Free State on Vimeo.

News Archive

Suspension of the South African Doping Control Laboratory (SADoCoL) by the World Anti-Doping Agency (WADA)
2016-05-04

The senior leadership of the UFS and the management of the South African Doping Control Laboratory (SADoCoL) take note of the decision by the World Anti-Doping Agency (WADA) to suspend the laboratory’s accreditation to perform doping control analysis on biological samples of athletes and sportsmen and -women until 30 September 2016. During this time of suspension, all sport-related samples will be sent for analysis to the WADA accredited laboratory in Qatar until the accreditation of SADoCoL is re-established. Analysis according to WADA accreditation will therefore not be interrupted during the period of the suspension of the accreditation of SADoCoL.

The announcement by WADA on 3 May 2016 follows a voluntary decision by SADoCoL in March 2016 to temporarily close the laboratory for some of its routine analytical duties for six months, as from 1 April 2016. The decision was taken in consultation with the senior leadership of the UFS and other role players, especially the Department of Sport and Recreation of South Africa (SRSA) and the South African Institute for Drug-Free Sport (SAIDS). SADoCoL is a specialised service laboratory of the University of the Free State (UFS) and has been in existence for more than thirty years.

Due to the ever-increasing demands on the number, variety and analytical sensitivity of compounds to be analysed according to the Prohibited List of WADA, technical and infrastructure adaptations need to be implemented in the laboratory continuously to keep up with the demands. Over the last year, SADoCoL has drastically increased its capacity in both personnel and infrastructure, to a point where these changes can be implemented for optimal performance of the laboratory.  This has to be done while normal routine analysis continues, and it became clear that at present, implementation cannot be successfully accomplished together with the workload from normal routine analyses.

The time of suspension will be utilised to implement and test these new systems in order to achieve the standard presently required by WADA, as well as to perform development and improvements.  This development will be performed in close collaboration with other role players in the anti-doping movement in South Africa, such as SAIDS and SRSA. Scientific development aid will also be acquired from other doping control laboratories worldwide in order to assure that the high analytical quality is maintained and expanded to meet the fast growing challenges in this field. The progress of the process will be closely monitored, and the upgraded methodologies will then, after rigorous testing, be implemented to ensure that the required analytical quality is maintained so as to obtain re-accreditation by WADA at the conclusion of the suspension period.

Issued by: Lacea Loader (Director: Communication and Brand Management)
Telephone: +27(0)51 401 2584 or +27 (0) 83 645 2454
E-mail: news@ufs.ac.za
Fax: +27 (0) 51 444 6393

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept